25240 Cosentyx (secukinumab) for the treatment of adult onset pityriasis rubra pilaris: A single arm, open-label exploratory study

Abstract

This prospective, single-arm, open label pilot study evaluated the clinical efficacy of secukinumab therapy in adult onset pityriasis rubra pilaris (PRP). A total of 10 patients with PRP were included. Baseline characteristics, Dermatology Life Quality Index (DLQI) score, Psoriatic Area and Severity Index (PASI) score, Physician Global Assessment (PGA), and adverse events were collected. Reduction in PASI score by ≥75% of baseline value and by ≥90% of baseline value were calculated at week 12 and week 28.